Abstract
Abstract Introduction: Radiation treatment is required by 70% of cancer patients, however there is currently no clinical method for determining the therapeutic response or radiation induced toxicity that can be used during a course of radiation therapy to personalize the dose for individual patients. The only standard method is CT/PET and/or MRI. This is a major clinical concern for radiation oncologists with so many new agents being approved in combination with radiation therapy. Methodology: Herein we describe a highly sensitive clinically validated assay that measures the extent of normal tissue damage induced by radiation by quantitation of circulating free DNA (cfDNA) derived from cellular apoptosis detected in plasma of patients undergoing radiation therapy. The assay employs DNA capture probes and SuperbDNATM signal amplification technology with alkaline phosphatase labelled signaling probes coupled with dioxetane phosphate chemiluminescence detection. The assay can be performed directly on patient plasma samples and can be readily automated. Conclusion: RadTox TM can be used both for research and clinical testing of plasma samples for patients undergoing radiation therapy for optimization and personalization of treatment. Citation Format: Paul OKunieff, Steven Swarts, Elena Peletskya, Anne Vallerga, Rachel Chuang, Michael J. Powell, Aiguo Zhang. Novel predictive biomarker for monitoring adverse reactions to radiation therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4748. doi:10.1158/1538-7445.AM2017-4748
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
